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A missense mutation within the APC gene, Isoleucine to Lysine
alteration in codon 1307 (I1307K), has been described in Jewish
individuals of East European descent (Ashkenazi), both at risk for
colorectal cancer (CRC), and also in the general, average risk,
population of the same ethnic extraction (Laken et al, 1997;
Woodage et al, 1998). Studies involving I1307K carriers have
shown a moderate increase (up to 2-fold) in colon cancer risk
(Laken et al, 1997; Woodage et al, 1998; Rozen et al, 1999; Gryfe
et al, 1999). This specific polymorphism was considered to be
limited to Ashkenazi Jews (Laken et al, 1997; Prior et al, 1999),
but it was also reported in Jewish individuals of non-Ashkenazi
origin (Rozen et al, 1999; Patael et al, 1999; Drucker et al, 2000;
Shtoyerman et al, 2001), as well as non-Jewish individuals (Yuan
et al, 1998; Nathanson et al, 1999). Yet, the rate of this mutation in
the Jewish Ashkenazi population (5–7%) (Laken et al, 1997;
Woodage et al, 1998) and among patients with familial CRC (up to
28%) (Laken et al, 1997) facilitates large-scale analysis of this
mutation in unselected Jewish sub-populations. While most
studies tend to support the role this missense mutation plays in
conferring an increased risk to CRC (Woodage et al, 1998; Gryfe
et al, 1999), little information exists as to the phenotypic features
of mutation-associated CRC. Some studies claimed that mutation
carriers have an earlier age at onset of CRC as compared with the
general population (Laken et al, 1997; Gryfe et al, 1999), or an
association with multiple colonic adenomas (Gryfe et al, 1999).
We determined the phenotypic features of 307 unselected CRC
patients who were treated in a single medical centre in Israel, and
compared these features in I1307K mutation carriers with non-
carriers. 
MATERIALS AND METHODS 
Patients 
All analysed patients had clinical and pathological confirmation of
CRC, and were being treated and followed-up at the Oncology
Institute at the Rabin Medical Center (Belinson campus). The
institutional review board approved the study, and each participant
signed a written informed consent. All clinical details were
retrieved by a detailed questionnaire filled by the patients, and
extraction of data from the medical records and pathology reports.
Patients who fulfilled the Amsterdam or Bethesda II criteria for
HNPCC (OMIM # 114500) (OMIM database), were excluded
from analysis. 
DNA extraction 
Genomic DNA was prepared from anticoagulated venous blood
samples using standard techniques, employing the Gentra Kit
(Gentra Inc., Minneapolis, MN) and using the manufacturer’s
recommended protocol. 
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Analysis of the I1307K mutation 
I1307K mutation detection included PCR amplification of the
relevant genomic region, and subjecting the resulting PCR product
to analysis by denaturing gradient gel electrophoresis (DGGE) as
detailed elsewhere (Patael et al, 1999), or a modified restriction
analysis (MRA), as detailed elsewhere by us (Shtoyerman et al,
2001). All consistently abnormally migrating fragments (i.e.,
repeated abnormalities on three independent PCRs) were subject
to sequence analysis using the big Dye terminator chemistry and
kit (PE Biosystems, Foster City, CA), and using the ABI Prism
310 semiautomatic DNA sequencer (PE Biosystems). 
Statistical analysis 
Statistical analysis was performed using the Chi square test or the
Fisher Exact test where appropriate. Mann-Whitney test was used
to compare ordinal variables between the two groups. When a non-
statistically significant result was obtained, power calculations
were performed. These calculations were based on the estimated
parameters among carriers, at effect size deemed to be biologically
important, using the same sample size. 
RESULTS 
Overall patients’ characteristics 
Overall, 307 patients were analysed: 170 men and 137 women.
There were 189 patients of Ashkenazi origin (61.6%), 80 non-
Ashkenazis (26%) (30 of Iraqi origin, 21 of North African origin,
11 of Balkan origin, and 18 of Yemenite extraction). There were
22 mixed Israeli-Ashkenazis, 14 Mixed Israeli non-Ashkenazis,
and 2 Israeli Arabs. A total of 118 patients (38.4%) had first
degree relatives with cancer: 55 (17.9%) had relatives with CRC,
53 with non-gastrointestinal tract tumours, and in 10 patients –
other malignancies that were not specified were noted in relatives.
Disease stage in the majority of patients (188 – 61.2%) was Dukes
B, and in 74 (24.1%) Dukes C. The majority of tumours were
either well differentiated (66 – 21.5%) or moderately differenti-
ated (178 – 58%). Tumours were most commonly located at the
rectosigmoid region (n = 172 – 56%), and in 74 (24.2%) the
tumour was located in the right colon. 
Comparison of the I1307K mutation carriers with 
non-carriers 
There were 28 (9.1%) I1307K mutation carriers, and the rest were
non-carriers. The age at diagnosis, sex, ethnic origin, disease grade
and stage, tumour location and family history of cancer in carriers
compared with non-carriers is shown in Table 1. As is evident
from the table, mean age at diagnosis of carriers (65.0 +/– 9.7
years) is not significantly different than that of non-carriers (66.3
+/– 11.6 years). Assuming that carriers are 5 years younger than
non-carriers, our sample gave a power that was equal to 0.88. The
features that statistically differed in mutation carriers and non-
carriers are the predicted paucity of non-Ashkenazis among muta-
tion carriers (2–7.1%) compared with the rate among non-carriers
(93 – 33.6%) (P < 0.01). In 74 (26.6%) of the sporadic cases and
only one mutation carrier (3.6%), the tumour was located in the
right colon (P < 0.01), and in 15 mutation carriers (53.6%) disease
stage was Dukes C or higher (53.6%) compared with 80 (28%) of
non carriers (P = 0.02). For the parameters that were not signifi-
cantly different between carriers and non-carriers, power calcula-
tions were carried out. To detect a two-fold difference in positive
family history of colon or other cancer in carriers and a two fold
increase in the proportion of more advanced disease (poorly and
undifferentiated) in carriers our sample size was clearly inade-
quate, giving power of 0.33 and 0.15, respectively. 
DISCUSSION 
In this study, most of the phenotypic features of CRC in
I1307K mutation carrier did not markedly differ from those of
non-mutation carriers. Notably, age at diagnosis and the rate of a
positive family history of cancer were similar in carriers and non-
carriers. This finding is counter-intuitive, as the prevailing para-
digm of cancer susceptibility genes predicts that mutation carriers
will exhibit early age at onset, and have a personal or a family
history of cancer more frequently than sporadic cases. The find-
ings of a similar age at onset and family history of cancer in muta-
tion carriers and non-carriers reported herein are consistent with
another study (Drucker et al, 2000). Taken together with the
Table 1 Comparison of the phenotypic features of I1307K mutation carriers
as compared with non-carriers 
Parameter I1307K carriers Non-carriers P value 
(n = 28) (%) (n = 279) (%) 
Age at diagnosis NS 
Range 38–83 26–89 
Mean +/– SD 65.0 ± 9.7 66.3 ± 11.6 
Sex NS 
Males 12 (42.9) 158 (56.6) 
Females 16 121 
Ethnic origin 
Ashkenazis 23 (92.3)* 166 (66.3)* 
Non-Ashkenazis (Total) 2 (7.1) 93 (33.6) 0.01 
Asia 1 29 
North Africa 21 
Balkan 11 
Yemen 18 
Mixed Ashkenazis 3 19 
Mixed non-Ashkenazis 1 13 
Arab-Israelis 2 
Family history of Cancer NS 
Colon 5 50 
Other 5 58 
Tumour Location 0.01 
Right colon 1 (3.6) 74 (26.6)** 
Transverse 7 (25) 20 (7.2) 
Left colon 8 (28.6) 110 (39.7) 
Rectum 12 (42.9) 73 (26.4) 
Tumour grade NS 
Well Differ 6 (21.4) 60 (21.5) 
Moderate Differ 17 (60.7) 161 (57.7) 
Poorly Differ 2 (7.1) 21 (7.5) 
Undifferentiated – 1 (0.4) 
Unknown 3 (10.7) 36 (12.9) 
Disease Stage 0.02*** 
Dukes A – 12 (4.3) 
Dukes B 13 (46.4) 175 (62.7) 
Dukes C 14 (50) 60 (21.5) 
Distant metastases 1 (3.6) 20 (7.2) 
Unrecorded – 12 (4.3) 
*Includes the Mixed Ashkenazis; **For two non-carriers, the tumour location
was unrecorded; ***Mann Whitney test applied. 1370 A Figer et al
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reports that adenomatous colonic polyps were not more prevalent
in I1307K mutation carriers compared with non-carriers (Syngal 
et al, 2000; Stern et al, 2001), these findings imply that the I1307K
APC mutation confers a moderate increased lifetime risk for CRC
(Woodage et al, 1998; Gryfe et al, 1999). Yet, the classical pheno-
typic parameters used for identifying individuals at risk for
harbouring a germline mutation in cancer susceptibility gene may
not be directly applied for the I1307K APC mutation. Thus, this
missense mutation may prove to be one of several ‘functional
polymorphisms’, each with a moderate effect of increasing cancer
risk, with the combined effect in carriers of many of these poly-
morphisms, manifesting as CRC. 
The I1307K mutation was originally described among
Ashkenazi Jews (Laken et al, 1997), where it occurs at a rate of up
to 7% of the general population (Woodage et al, 1998). However,
this mutation was reported at a significantly lower rate in non-
Ashkenazi Jews (Rozen et al, 1999; Patael et al, 1998) and anecdo-
tally in non-Jewish individuals (Yuan et al, 1998; Nathanson et al,
1999). In fact, we previously showed that the mutation probably
represents a founder mutation in Jewish individuals (Patael 
et al, 1998), as was also confirmed by other investigators
(Woodage et al, 1998). Drucker et al (2000), reported that the
I1307K mutation was detected in 3/4 Yemenite Jewish individuals,
whereas in the present study this mutation could not be detected in
any of 18 Yemenite Jews with CRC. This discrepancy cannot be
logically settled, until more individuals of Yemenite extraction are
tested. The age standardized rate (ASR) of CRC in Ashkenazis 
in Israel is 41.9/100 000 and in non-Ashkenazis, including
Yemenites–25.5/100 000 (Israel Cancer Registry, 1998). This
reality of CRC epidemiology in Israel intuitively suggests that the
rate of this missense mutation is lower in Yemenites than in
Ashkenazis. If indeed this mutation contributes to CRC pathogen-
esis in the general population, than one must assume that modifier
factors, such as environmental exposures, personal habits, nutri-
tional factors and modifier genes affect the phenotypic expression
of this mutation in Yemenite Jews. 
Mutation carriers had a more advanced disease stage, in line
with the observations from another study from Israel (Drucker
et al, 2000). Yet, several differences exist between the data
presented herein and the study by Drucker and co-workers (2000).
In that study, tumours in mutation carriers tended to cluster to the
right colon and have a more favourable histological grade,
whereas neither was observed in our study population. Moreover,
more than 40% of mutation carriers displayed rectal cancer, a high
rate compared with non-carriers in this study or in unselected
series of colo-rectal cancer patients in Israel (Israel Cancer
Registry, 1998). One possible explanation is that there are differ-
ences in the selection criteria between the two medical centres.
This seems unlikely, as both medical centres are located in the
same geographical region of Israel, and both attract the same
ethnic profile of patients. Another possibility is that the small
number of analysed patients in both studies combined prevent firm
conclusions as to the putative role that the I1307K plays in
affecting the phenotypic features of CRC. The published studies
that addressed the issue of the phenotypic features of colon cancer
in I1307K APC mutation carriers are summarized in Table 2. The
inconclusive and at times conflicting results from these studies
indicate that a much larger study, encompassing a large number of
individuals, with a longer follow-up is urgently needed. 
The notion that the phenotype of CRC in I1307K mutation
carriers is for the most part similar to that of non-carriers, is
indirectly supported by the study of Syngal and co-workers
(2000). In that study, the phenotypic features of adenomatous
polyps, as well as the family history of cancer, did not differ in
mutation carriers as compared with non-carriers. 
In conclusion, early age at diagnosis or family history of CRC or
right-sided tumour are poor predictors of detecting the I1307K
APC mutation, and with the possible exception of a more
advanced disease stage, the phenotypic features of CRC are
similar in mutation carriers and non-carriers. 
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